Bevacizumab was the first FDA-approved monoclonal antibody targeting VEGF-A for colorectal cancer (CRC) therapy and has shown significant improvements in overall and progression-free survival in patients with metastatic CRC.396 With advancements in basic research and clinical trials, bevacizumab is now used for a broader range of solid malignancies, including ovarian cancer,397 glioma,398 hepatocellular carcinoma (HCC),22 cervical cancer,11 and renal cell carcinoma.399. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.